Participants in the highest Neurodegenerative Delay (MIND)

Added on April 29, 2025

Address: 2038 Jewell Road

Business Email: frenzinaomi@gmail.com

Contact: +916127027194

Website: https://phimmoi.tech.blog/2025/04/29/danh-gia-phim-mat-danh-ke-toan-2-giai-tri-va-khong-dong-deu-phimmoichill/

Healthy aging at 70 years and a 2.2-fold higher likelihood of healthy aging at 75 years compared to those in the lowest quintile of the AHEI score. The AHEI diet reflects a diet rich in fruits, vegetables, whole grains, nuts, legumes, and healthy fats and low in red and processed meats, sugar-sweetened beverages, sodium, and refined grains. Another leading diet for healthy aging was the PHDI, which considers both human and environmental health by emphasizing plant-based foods and minimizing animal-based foods.

Extreme heat has a detrimental impact on athletic performance, says Mike Tipton, co-author of the Rings of Fire report and professor of physiology at the University of Portsmouth’s Extreme Environments Laboratory in the UK.
“As the temperature goes up, you get a reduction in performance – marathon performance declines by about one minute for every 1C (1.8F) increase in air temperature above 15C (59F),” says Tipton.
The ideal temperature for continuous endurance, such as cycling or running, is 11C (51.8F), says Tipton.

“Yogurt may be good for maintaining a good microbiome in our body,” says Dr. Tomotaka Ugai, a co-senior author of the study. He’s an investigator at Brigham and Women’s Hospital and a department associate at the Harvard T.H. Chan School of Public Health.

Specifically, the researchers found that the habitual yogurt eaters had lower rates of Bifidobacterium-positive proximal colon cancers. Proximal colon cancer is a type of colon cancer that occurs on the right side of the colon and can have worse survival outcomes than cancers that occur in the distal colon, which is on the left side.

Ugai says the bacteria in yogurt appear to promote an overall healthy balance of bacteria in the gut. And that, in turn, promotes a strong and healthy gut barrier, which is important, because when the gut barrier becomes too permeable, it can lead to inflammation and increase the risk of colon cancer.

“My message is, if you like yogurt, go for it,” Ugai says.

Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) showed higher rates of invasive-disease-free survival and overall survival as compared to trastuzumab (Herceptin) alone for patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy, as demonstrated in results from the KATHERINE trial (NCT01772472).1

“This prespecified long-term follow-up analysis provides additional support for the neoadjuvant therapy paradigm by showing that adjuvant T-DM1 also provided a significant improvement in overall survival and no evidence of long-term safety issues,” wrote KATHERINE investigators in The New England Journal of Medicine.

Patients enrolled in the phase 3, open-label trial continued to see an improvement in invasive disease-free survival with T-DM1 vs trastuzumab at a median follow-up of 8.4 years (unstratified HR = 0.54; 95% CI, 0.44-0.66). Particularly, 19.7% of patients in the T-DM1 group and 32.2% of patients in the trastuzumab group experienced invasive disease events or death.

Seven-year invasive disease-free survival was achieved in 80.8% of patients treated with T-DM1 and 67.1% of patients on trastuzumab (difference, 13.7 percentage points).

The trial included patients with HER2-positive early breast cancer who had received neoadjuvant treatment, which included a taxane-based chemotherapy and/or trastuzumab, and had residual invasive cancer in the breast or resected axillary nodes. Patients were randomly assigned to receive either T-DM1 (n = 743) or trastuzumab (n = 743). Patients were stratified by clinical stage, hormone-receptor status, preoperative HER2-directed therapy, and pathological nodal status after neoadjuvant therapy.

T-DM1 significantly reduced the risk for death compared with trastuzumab (unstratified HR = 0.66; 95% CI, 0.51-0.87; P = .003). Seven-year overall survival for the T-DM1 and trastuzumab groups were 89.1% and 84.4%, respectively (difference, 4.7 percentage points). As of the trial’s cutoff date of October 5, 2023, 70.1% of patients assigned T-DM1 and 62.0% of patients assigned trastuzumab were alive and still in the trial.

Participants in the highest Neurodegenerative Delay (MIND)

Trakky

SeniorCare EMS

Arimidex 1mg Tablet: Most effective medicine for the treatment of Breast Cancer

Plant Powered Health

Dr. Bharti's Holistic Wellness

Clear Skin Clinic

Emergency Ambulance Service in Varanasi | AMPLifier

Discover the Power of Moringa and Yerba Magic

Participants in the highest Neurodegenerative Delay (MIND)

Sign In

Register

Reset Password